Literature DB >> 19415436

Vagus nerve stimulation in drug-resistant daily chronic migraine with depression: preliminary data.

Alberto Proietti Cecchini1, Eliana Mea, Vincenzo Tullo, Marcella Curone, Angelo Franzini, Giovanni Broggi, Mario Savino, Gennaro Bussone, Massimo Leone.   

Abstract

Drug refractory chronic daily headache (CDH) is a highly disabling condition. CDH is usually regarded as the negative evolution of chronic migraine (CM) and is characterized by high prevalence of psychiatric disorders, especially mood disorders. Vagal nerve stimulation (VNS) is an established treatment option for selected patients with medically refractory epilepsy and depression. Neurobiological similarities suggest that VNS could be useful in the treatment of drug-refractory CM associated with depression. The aim of the study was to evaluate the efficacy of VNS in patients suffering from drug-refractory CM and depressive disorder. We selected four female patients, mean age 53 (range 43-65 years), suffering from daily headache and drug-refractory CM. Neurological examination and neuroradiological investigations were unremarkable. Exclusion criteria were psychosis, heart and lung diseases. The preliminary results in our small case series support a beneficial effect of chronic VNS on both drug-refractory CM and depression, and suggest this novel treatment as a valid alternative for this otherwise intractable and highly disabling condition.

Entities:  

Mesh:

Year:  2009        PMID: 19415436     DOI: 10.1007/s10072-009-0073-3

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  10 in total

1.  Prospective long-term study of vagus nerve stimulation for the treatment of refractory seizures.

Authors:  C M DeGiorgio; S C Schachter; A Handforth; M Salinsky; J Thompson; B Uthman; R Reed; S Collins; E Tecoma; G L Morris; B Vaughn; D K Naritoku; T Henry; D Labar; R Gilmartin; D Labiner; I Osorio; R Ristanovic; J Jones; J Murphy; G Ney; J Wheless; P Lewis; C Heck
Journal:  Epilepsia       Date:  2000-09       Impact factor: 5.864

2.  Two-year outcome of vagus nerve stimulation (VNS) for treatment of major depressive episodes.

Authors:  Ziad Nahas; Lauren B Marangell; Mustafa M Husain; A John Rush; Harold A Sackeim; Sarah H Lisanby; James M Martinez; Mark S George
Journal:  J Clin Psychiatry       Date:  2005-09       Impact factor: 4.384

Review 3.  Migraine-associated risks and comorbidity.

Authors:  H C Diener; M Küper; T Kurth
Journal:  J Neurol       Date:  2008-09-30       Impact factor: 4.849

Review 4.  Pain control by vagus nerve stimulation: from animal to man...and back.

Authors:  Sylvie Multon; Jean Schoenen
Journal:  Acta Neurol Belg       Date:  2005-06       Impact factor: 2.396

Review 5.  Relation between migraine and stroke.

Authors:  Marie-Germaine Bousser; K Michael A Welch
Journal:  Lancet Neurol       Date:  2005-09       Impact factor: 44.182

6.  Comorbidity of migraine and psychiatric disorders--a national population-based study.

Authors:  Nathalie Jette; Scott Patten; Jeanne Williams; Werner Becker; Samuel Wiebe
Journal:  Headache       Date:  2007-12-07       Impact factor: 5.887

7.  The effect of vagus nerve stimulation on migraines.

Authors:  E Daniela Hord; M Steven Evans; Sajjad Mueed; Bola Adamolekun; Dean K Naritoku
Journal:  J Pain       Date:  2003-11       Impact factor: 5.820

Review 8.  When should "chronic migraine" patients be considered "refractory" to pharmacological prophylaxis?

Authors:  Domenico D'Amico; Massimo Leone; Licia Grazzi; Gennaro Bussone
Journal:  Neurol Sci       Date:  2008-05       Impact factor: 3.307

Review 9.  Therapeutic neurostimulation in chronic headaches: problems of patient selection.

Authors:  Massimo Leone; Alberto Proietti Cecchini; Eliana Mea; Domenico D'Amico; Vincenzo Tullo; Licia Grazzi; Gennaro Bussone
Journal:  Neurol Sci       Date:  2008-05       Impact factor: 3.307

Review 10.  Vagus nerve stimulation therapy, epilepsy, and device parameters: scientific basis and recommendations for use.

Authors:  Christi Heck; Sandra L Helmers; Christopher M DeGiorgio
Journal:  Neurology       Date:  2002-09-24       Impact factor: 9.910

  10 in total
  30 in total

Review 1.  Surgical treatment of primary headaches.

Authors:  Angelo Franzini; Giuseppe Messina; Roberto Cordella; Alberto Proietti Cecchini; Massimo Leone; Gennaro Bussone
Journal:  Neurol Sci       Date:  2012-05       Impact factor: 3.307

Review 2.  [Therapeutic neuromodulation in primary headaches].

Authors:  A May; T P Jürgens
Journal:  Nervenarzt       Date:  2011-06       Impact factor: 1.214

Review 3.  Neurostimulation for Treatment of Migraine and Cluster Headache.

Authors:  Todd J Schwedt; Bert Vargas
Journal:  Pain Med       Date:  2015-07-14       Impact factor: 3.750

Review 4.  Supratrochlear and Supraorbital Nerve Stimulation for Chronic Headache: a Review.

Authors:  Stephanie Wrobel Goldberg; Stephanie J Nahas
Journal:  Curr Pain Headache Rep       Date:  2015-07

Review 5.  Non-Invasive Neuromodulation for Headache Disorders.

Authors:  Shuhan Zhu; Michael J Marmura
Journal:  Curr Neurol Neurosci Rep       Date:  2016-02       Impact factor: 5.081

Review 6.  Neuromodulation for intractable headaches.

Authors:  Roya Hassanzadeh; Jeremy C Jones; Edgar L Ross
Journal:  Curr Pain Headache Rep       Date:  2014-02

Review 7.  New treatments for headache.

Authors:  Sarah Vollbracht; Alan M Rapoport
Journal:  Neurol Sci       Date:  2014-05       Impact factor: 3.307

Review 8.  Peripheral neurostimulation in primary headaches.

Authors:  Giorgio Lambru; Manjit Singh Matharu
Journal:  Neurol Sci       Date:  2014-05       Impact factor: 3.307

Review 9.  The pipeline in headache therapy.

Authors:  Sarah Vollbracht; Alan M Rapoport
Journal:  CNS Drugs       Date:  2013-09       Impact factor: 5.749

Review 10.  Invasive and Non-invasive Electrical Pericranial Nerve Stimulation for the Treatment of Chronic Primary Headaches.

Authors:  Kevin D'Ostilio; Delphine Magis
Journal:  Curr Pain Headache Rep       Date:  2016-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.